Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Lin, Chih Wei ^a   Liu, Chia Chyi ^a   Lu, Tsung Chun ^a   Liu, Shih Jen ^a,b   Chow, Yen Hung ^a   Chong, Pele ^a,b   Huang, Ming Hsi ^a,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CPG OLIGODEOXYNUCLEOTIDE; ENTEROVIRUS 71 COXSACKIE VIRUS A16 VACCINE; ENTEROVIRUS 71 VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE; CPG-OLIGONUCLEOTIDE; EMULSION; EPITOPE; IMMUNOGLOBULIN G; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; COXSACKIE VIRUS A16; EMULSION; ENTEROVIRUS 71; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; SEROCONVERSION; SINGLE DRUG DOSE; VERO CELL LINE; VIRION; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CHLOROCEBUS AETHIOPS; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; PARTICLE SIZE; SERODIAGNOSIS;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; EMULSIONS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; OLIGODEOXYRIBONUCLEOTIDES; PARTICLE SIZE; PEPTIDES; VERO CELLS; VIRAL VACCINES; VIRION;

EID: 84903641453     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/670506     Document Type: Article

References (29)

1. World Health Organization, A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD) 2011
2. Ooi M. H., Wong S. C., Lewthwaite P., Cardosa M. J., Solomon T., Clinical features, diagnosis, and management of enterovirus 71. The Lancet Neurology 2010 9 11 1097 1105 2-s2.0-77957953975 10.1016/S1474-4422(10)70209-X
3. Solomon T., Lewthwaite P., Perera D., Cardosa M. J., McMinn P., Ooi M. H., Virology, epidemiology, pathogenesis, and control of enterovirus 71. The Lancet Infectious Diseases 2010 10 11 778 790 2-s2.0-78049398279 10.1016/S1473-3099(10)70194-8
4. Chong P., Hsieh S.-Y., Liu C.-C., Chou A.-H., Chang J.-Y., Wu S.-C., Liu S.-J., Chow Y.-H., Su I.-J., Klein M., Production of EV71 vaccine candidates. Human Vaccines and Immunotherapeutics 2012 8 12 1775 1783 2-s2.0-84872249666 10.4161/hv.21739
5. Cheng A., Fung C.-P., Liu C.-C., Lin Y.-T., Tsai H.-Y., Chang S.-C., Chou A.-H., Chang J.-Y., Jiang R.-H., Hsieh Y.-C., Su I.-J., Chong P. C.-S., Hsieh S.-M., A phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013 31 20 2471 2476 2-s2.0-84877072126 10.1016/j.vaccine.2013.03.015
6. Zhu F.-C., Meng F.-Y., Li J.-X., Li X.-L., Mao Q.-Y., Tao H., Zhang Y.-T., Yao X., Chu K., Chen Q.-H., Hu Y.-M., Wu X., Liu P., Zhu L.-Y., Gao F., Jin H., Chen Y.-J., Dong Y.-Y., Liang Y.-C., Shi N.-M., Ge H.-M., Liu L., Chen S.-G., Ai X., Zhang Z.-Y., Ji Y.-G., Luo F.-J., Chen X.-Q., Zhang Y., Zhu L.-W., Liang Z.-L., Shen X.-L., Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2013 381 9882 2024 2032 2-s2.0-84878653325 10.1016/S0140-6736(13)61049-1
7. Zhu F., Xu W., Xia J., Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. The New England Journal of Medicine 2014 370 9 818 828 10.1056/NEJMoa1304923
8. Li R., Liu L., Mo Z., An inactivated enterovirus 71 vaccine in healthy children. The New England Journal of Medicine 2014 370 9 829 837 10.1056/NEJMoa1303224
9. Chong P., Guo M.-S., Lin F. H.-Y., Hsiao K.-N., Weng S.-Y., Chou A.-H., Wang J.-R., Hsieh S.-Y., Su I.-J., Liu C.-C., Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS ONE 2012 7 11 2-s2.0-84870600954 10.1371/journal.pone.0049973 e49973
10. Cai Y., Liu Q., Huang X., Li D., Ku Z., Zhang Y., Huang Z., Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013 31 18 2215 2221 2-s2.0-84875844319 10.1016/j.vaccine.2013.03.007
11. Vogel F. R., Caillet C., Kusters I. C., Haensler J., Emulsion-based adjuvants for influenza vaccines. Expert Review of Vaccines 2009 8 4 483 492 2-s2.0-65449178107 10.1586/erv.09.5
12. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., O'Hagan D., Rappuoli R., De Gregorio E., Molecular and cellular signatures of human vaccine adjuvants. Proceedings of the National Academy of Sciences of the United States of America 2008 105 30 10501 10506 2-s2.0-48749120743 10.1073/pnas.0804699105
13. Huang M.-H., Huang C.-Y., Lin S.-C., Chen J.-H., Ku C.-C., Chou A.-H., Liu S.-J., Chen H.-W., Chong P., Leng C.-H., Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes and Infection 2009 11 6-7 654 660 2-s2.0-67649210791 10.1016/j.micinf.2009.03.003
14. Huang M.-H., Lin S.-C., Hsiao C.-H., Chao H.-J., Yang H.-R., Liao C.-C., Chuang P.-W., Wu H.-P., Huang C.-Y., Leng C.-H., Liu S.-J., Chen H.-W., Chou A.-H., Hu A. Y.-C., Chong P., Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS ONE 2010 5 8 2-s2.0-77957906849 10.1371/journal.pone.0012279 e12279
15. Lin S.-C., Huang M.-H., Tsou P.-C., Huang L.-M., Chong P., Wu S.-C., Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS ONE 2011 6 5 2-s2.0-79957796724 10.1371/journal.pone.0020052 e20052
16. Lin S.-C., Jan J.-T., Dionne B., Butler M., Huang M.-H., Wu C.-Y., Wong C.-H., Wu S.-C., Different immunity elicited by recombinant H5N1 hemagglutinin proteins containing pauci-mannose, high-mannose, or complex type N-glycans. PLoS ONE 2013 8 6 2-s2.0-84879177723 10.1371/journal.pone.0066719 e66719
17. Lin C. W., Chang C. Y., Chen W. L., Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV. Human Vaccine & Immunotherapeutics 2013 9 11 2378 2385
18. Liu C.-C., Guo M.-S., Lin F. H.-Y., Hsiao K.-N., Chang K. H.-W., Chou A.-H., Wang Y.-C., Chen Y.-C., Yang C.-S., Chong P. C.-S., Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS ONE 2011 6 5 2-s2.0-79955938192 10.1371/journal.pone.0020005 e20005
19. Liu C.-C., Chou A.-H., Lien S.-P., Lin H.-Y., Liu S.-J., Chang J.-Y., Guo M.-S., Chow Y.-H., Yang W.-S., Chang K. H.-W., Sia C., Chong P., Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 2011 29 26 4362 4372 2-s2.0-79957836497 10.1016/j.vaccine.2011.04.010
20. Berger R., Just M., Gluck R., Interference between strains in live virus vaccines I: combined vaccination with measles, mumps and rubella vaccine. Journal of Biological Standardization 1988 16 4 269 273 2-s2.0-0023684853 (Pubitemid 18262921)
21. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., Jourdier T.-M., Ramirez L., Gregoire V., Charnay C., Burdin N., Dumas R., Lang J., Evaluation of interferences between dengue vaccine serotypes in a monkey model. The American Journal of Tropical Medicine and Hygiene 2009 80 2 302 311 2-s2.0-59649124328
22. Sun W., Edelman R., Kanesa-Thasan N., Eckels K. H., Putnak J. R., King A. D., Houng H.-S., Tang D., Scherer J. M., Hoke C. H. Jr., Innis B. L., Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. The American Journal of Tropical Medicine and Hygiene 2003 69 6 24 31 2-s2.0-1342267637
23. Wang W., Singh M., Selection of adjuvants for enhanced vaccine potency. World Journal of Vaccine 2011 1 2 33 78 10.4236/wjv.2011.12007
24. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., Hagan D. T., Podda A., Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. The Pediatric Infectious Disease Journal 2009 28 7 563 571 2-s2.0-67651115689 10.1097/INF.0b013e31819d6394
25. + T-cell-mediated anti-tumor immunity. Journal of Control Release 2014 173 158 165 10.1016/j.jconrel.2013.10.027
26. Wheeler C. M., Castellsagué X., Garland S. M., Szarewski A., Paavonen J., Naud P., Salmerón J., Chow S.-N., Apter D., Kitchener H., Teixeira J. C., Skinner S. R., Jaisamrarn U., Limson G., Romanowski B., Aoki F. Y., Schwarz T. F., Poppe W. A. J., Bosch F. X., Harper D. M., Huh W., Hardt K., Zahaf T., Descamps D., Struyf F., Dubin G., Lehtinen M., Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology 2012 13 1 100 110 2-s2.0-84855309413 10.1016/S1470-2045(11)70287-X
27. Chang L.-Y., Hsiung C. A., Lu C.-Y., Lin T.-Y., Huang F.-Y., Lai Y.-H., Chiang Y.-P., Chiang B.-L., Lee C.-Y., Huang L.-M., Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatric Research 2006 60 4 466 471 2-s2.0-33748897695 10.1203/01.pdr. 0000238247.86041.19 (Pubitemid 44427602)
28. Lin Y.-W., Yu S.-L., Shao H.-Y., Lin H.-Y., Liu C.-C., Hsiao K.-N., Chitra E., Tsou Y.-L., Chang H.-W., Sia C., Chong P., Chow Y.-H., Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS ONE 2013 8 2 2-s2.0-84874378993 10.1371/journal.pone.0057591 e57591
29. Chang H.-W., Lin Y.-W., Ho H.-M., Lin M.-H., Liu C.-C., Shao H.-Y., Chong P., Sia C., Chow Y.-H., Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS ONE 2013 8 7 2-s2.0-84880802401 10.1371/journal.pone.0069858 e69858